Nobuhiro Tahara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nobuhiro Tahara has a total of 346 co-authors. Here are the top co-authors by number of shared publications:
Yoshihiro Fukumoto
Division of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Kurume, Japan
72 shared publicationsAkihiro Honda
Division of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Kurume, Japan
52 shared publicationsAtsuko Tahara
Division of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Kurume, Japan
49 shared publicationsMunehisa Bekki
Division of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Kurume, 67 Asahi-Machi, Kurume 830-0011, Japan
38 shared publicationsSachiyo Igata
Division of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Kurume, Japan
35 shared publicationsYoichi Sugiyama
Division of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine , 67 Asahi-machi, Kurume 830-0011
35 shared publications
Latest Publications
- Open Access
- 30 August 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (11) , 4047-4055
Eplontersen with and without background transthyretin stabilizers in transthyretin amyloid cardiomyopathy: secondary analysis of a phase 3, randomized controlled trial
Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) therapies include both TTR gene silencers and TTR stabilizers. The role of TTR gene silencers added to background TTR stabilizer therapy is unknown, and the effects of silencer treatment in the absence of stabilizer use are unclear. In the CARDIO-TTRansform study, 1,432 patients ( n = 135 (9.4%) women and n = 1,297 (90.6%) men) with ATTR-CM were randomized (1:1) and treated with the antisense oligonucleotide eplontersen (45 mg every 4 weeks) that targets TTR or with placebo for up to 140 weeks. At baseline, 57% of the patients were taking TTR stabilizers. In the overall study, treatment with eplontersen did not reduce the primary composite endpoint. Here, in a prespecified analysis, we show that the primary endpoint (a composite of cardiovascular mortality and recurrent cardiovascular events) was modified by baseline stabilizer use ( P interaction = 0.017). Benefits were observed in those patients not on stabilizers at baseline (rate ratio (RR) = 0.71, 95% confidence interval (CI) 0.54 to 0.93, P = 0.012), whereas no benefits were observed in those on stabilizers at baseline (RR = 1.14, 95% CI 0.85 to 1.53, P = 0.39). The safety profile of eplontersen was favorable, irrespective of baseline stabilizer use. Treatment with eplontersen versus placebo demonstrated a clinically meaningful benefit among patients not receiving background stabilizers but provided no additional clinical benefit in those on background stabilizer therapy. These findings of a strong treatment effect modification may offer insight for therapeutic decision-making in clinical practice. ClinicalTrials.gov registration: NCT04136171 .
- 30 August 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (11) , 4047-4055
Open AccessEplontersen with and without background transthyretin stabilizers in transthyretin amyloid cardiomyopathy: secondary analysis of a phase 3, randomized controlled trial
Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) therapies include both TTR gene silencers and TTR stabilizers. The role of TTR gene silencers added to background TTR stabilizer therapy is unknown, and the effects of silencer treatment in the absence of stabilizer use are unclear. In the CARDIO-TTRansform study, 1,432 patients ( n = 135 (9.4%) women and n = 1,297 (90.6%) men) with ATTR-CM were randomized (1:1) and treated with the antisense oligonucleotide eplontersen (45 mg every 4 weeks) that targets TTR or with placebo for up to 140 weeks. At baseline, 57% of the patients were taking TTR stabilizers. In the overall study, treatment with eplontersen did not reduce the primary composite endpoint. Here, in a prespecified analysis, we show that the primary endpoint (a composite of cardiovascular mortality and recurrent cardiovascular events) was modified by baseline stabilizer use ( P interaction = 0.017). Benefits were observed in those patients not on stabilizers at baseline (rate ratio (RR) = 0.71, 95% confidence interval (CI) 0.54 to 0.93, P = 0.012), whereas no benefits were observed in those on stabilizers at baseline (RR = 1.14, 95% CI 0.85 to 1.53, P = 0.39). The safety profile of eplontersen was favorable, irrespective of baseline stabilizer use. Treatment with eplontersen versus placebo demonstrated a clinically meaningful benefit among patients not receiving background stabilizers but provided no additional clinical benefit in those on background stabilizer therapy. These findings of a strong treatment effect modification may offer insight for therapeutic decision-making in clinical practice. ClinicalTrials.gov registration: NCT04136171 .
- Top Cited Papers
- 28 August 2026
- Published by Massachusetts Medical Society in New England Journal of Medicine
Eplontersen for Transthyretin Amyloid Cardiomyopathy
- 28 August 2026
- Published by Massachusetts Medical Society in New England Journal of Medicine
Top Cited PapersEplontersen for Transthyretin Amyloid Cardiomyopathy
- 16 July 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (16) , 2265-2267
Right Ventricular Glucose Metabolism Predicts Reverse Remodeling After Balloon Pulmonary Angioplasty in Inoperable CTEPH
- 16 July 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (16) , 2265-2267
Right Ventricular Glucose Metabolism Predicts Reverse Remodeling After Balloon Pulmonary Angioplasty in Inoperable CTEPH
- 6 June 2026
- Published by Elsevier in Journal of Cardiology
- Vol. 88 (5) , 344-352
FDG-PET/CT for cardiovascular disease: A systems-level imaging framework linking inflammation, metabolism, and neural stress
- 6 June 2026
- Published by Elsevier in Journal of Cardiology
- Vol. 88 (5) , 344-352
FDG-PET/CT for cardiovascular disease: A systems-level imaging framework linking inflammation, metabolism, and neural stress
- 4 June 2026
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 61, 102770
Right ventricular metabolic adaptation to afterload and heterogeneous right ventricular-pulmonary arterial coupling in pre-capillary pulmonary hypertension: An 18F-fluorodeoxyglucose positron emission tomography /cardiac magnetic resonance study
- 4 June 2026
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 61, 102770
Right ventricular metabolic adaptation to afterload and heterogeneous right ventricular-pulmonary arterial coupling in pre-capillary pulmonary hypertension: An 18F-fluorodeoxyglucose positron emission tomography /cardiac magnetic resonance study
- Top Cited PapersOpen Access
- 1 June 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (6) , e014205
Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy
BACKGROUND: Transthyretin amyloidosis with cardiomyopathy is a progressive, fatal disease characterized by deposition of extracellular misfolded transthyretin (TTR) in the myocardium. Eplontersen is an N-acetylgalactosamine ligand–conjugated antisense oligonucleotide targeting hepatocyte TTR messenger RNA to reduce the production of circulating TTR. METHODS: CARDIO-TTRansform is a Phase 3, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of eplontersen in transthyretin amyloidosis with cardiomyopathy. Key inclusion criteria include histological evidence of amyloid deposits or grade 2 to 3 cardiac uptake on cardiac scintigraphy in the absence of plasma cell dyscrasia, New York Heart Association class I–III, and end-diastolic interventricular septum thickness >12 millimeters. Participants were randomized 1:1 to receive eplontersen 45 mg or placebo, administered subcutaneously every 4 weeks for up to 140 weeks, followed by a 20-week post-treatment evaluation period or open-label extension. Participants received locally available standard of care, including unrestricted use of TTR stabilizers. The primary end point is a composite of cardiovascular mortality and recurrent clinical cardiovascular events through 140 weeks. Secondary end points, in order of testing hierarchy, include changes from baseline in 6-minute walk distance and Kansas City Cardiomyopathy Questionnaire overall summary score, recurrent cardiovascular events, all-cause mortality, the primary end point in the patient subgroup receiving stabilizers at baseline, and cardiovascular mortality. Echocardiography was performed in all participants, with cardiovascular magnetic resonance imaging and technetium scintigraphy in a subset. CONCLUSIONS: CARDIO-TTRansform is fully enrolled, with 1432 randomized participants who were dosed with study drug or placebo. As the largest transthyretin amyloidosis with cardiomyopathy study to date, it will evaluate whether eplontersen improves cardiovascular outcomes in patients receiving locally available standard of care, including TTR stabilizers. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04136171. URL: http://ClinicalTrialsRegister.eu ; Unique identifier: EudraCT number 2019-002835-27.
- 1 June 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (6) , e014205
Top Cited PapersOpen AccessRationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy
BACKGROUND: Transthyretin amyloidosis with cardiomyopathy is a progressive, fatal disease characterized by deposition of extracellular misfolded transthyretin (TTR) in the myocardium. Eplontersen is an N-acetylgalactosamine ligand–conjugated antisense oligonucleotide targeting hepatocyte TTR messenger RNA to reduce the production of circulating TTR. METHODS: CARDIO-TTRansform is a Phase 3, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of eplontersen in transthyretin amyloidosis with cardiomyopathy. Key inclusion criteria include histological evidence of amyloid deposits or grade 2 to 3 cardiac uptake on cardiac scintigraphy in the absence of plasma cell dyscrasia, New York Heart Association class I–III, and end-diastolic interventricular septum thickness >12 millimeters. Participants were randomized 1:1 to receive eplontersen 45 mg or placebo, administered subcutaneously every 4 weeks for up to 140 weeks, followed by a 20-week post-treatment evaluation period or open-label extension. Participants received locally available standard of care, including unrestricted use of TTR stabilizers. The primary end point is a composite of cardiovascular mortality and recurrent clinical cardiovascular events through 140 weeks. Secondary end points, in order of testing hierarchy, include changes from baseline in 6-minute walk distance and Kansas City Cardiomyopathy Questionnaire overall summary score, recurrent cardiovascular events, all-cause mortality, the primary end point in the patient subgroup receiving stabilizers at baseline, and cardiovascular mortality. Echocardiography was performed in all participants, with cardiovascular magnetic resonance imaging and technetium scintigraphy in a subset. CONCLUSIONS: CARDIO-TTRansform is fully enrolled, with 1432 randomized participants who were dosed with study drug or placebo. As the largest transthyretin amyloidosis with cardiomyopathy study to date, it will evaluate whether eplontersen improves cardiovascular outcomes in patients receiving locally available standard of care, including TTR stabilizers. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04136171. URL: http://ClinicalTrialsRegister.eu ; Unique identifier: EudraCT number 2019-002835-27.
- Open Access
- 1 May 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (22) , 108047
Pediatric Cardiac Arrest From Tumor-Associated Pulmonary Embolism
- 1 May 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (22) , 108047
Open AccessPediatric Cardiac Arrest From Tumor-Associated Pulmonary Embolism
- Open Access
- 1 April 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (2)
Right Ventricular Mechanical Dyssynchrony Reflects Hemodynamic Load in Pre‐Capillary Pulmonary Hypertension
Right ventricular (RV) mechanical dyssynchrony represents a maladaptive response to increased afterload in pulmonary hypertension (PH). However, its hemodynamic and biochemical determinants remain unclear. This study aimed to identify the clinical, hemodynamic, and biochemical correlates of RV dyssynchrony in patients with pre‐capillary PH. Thirty patients with pre‐capillary PH (83% female; age 56 ± 19 years), all without intraventricular conduction delay (QRS < 120 ms), underwent right heart catheterization, cardiac magnetic resonance imaging, and two‐dimensional speckle‐tracking echocardiography. RV dyssynchrony was quantified using the coefficient of variation of time‐to‐peak systolic strain in four mid‐basal RV segments (RV‐CV4) adjusted for heart rate. Mean pulmonary artery pressure (mPAP), pulmonary vascular resistance (PVR), and RV‐CV4 averaged 34.1 ± 11.2 mmHg, 522.3 (interquartile range, 289.4–692.6) dyn·s·cm −5 , and 0.134 ± 0.083, respectively, in a cohort with predominantly mild‐to‐moderate RV systolic dysfunction. RV dyssynchrony correlated significantly with mPAP ( β = 0.509) PVR ( β = 0.507), and RV‐pulmonary artery coupling ( β = −0.406) (all p < 0.05). In multivariate analysis, mPAP remained the sole independent predictor of RV dyssynchrony ( β = 0.509, 95% CI 0.001–0.006, p = 0.004), accounting for 26% of its variance. Neither RV end‐diastolic volume nor RV ejection fraction were independently associated with dyssynchrony. RV mechanical dyssynchrony reflects hemodynamic afterload, particularly elevated mPAP, rather than structural remodeling. Notably, dyssynchrony was evident even in mild‐to‐moderate RV dysfunction, indicating an early manifestation of pressure‐induced impairment. RV‐CV4 may serve as a noninvasive marker of pulmonary vascular load and highlight the importance of afterload reduction in optimizing RV mechanical coordination. Accordingly, RV dyssynchrony assessment may provide a practical echocardiographic surrogate for invasive hemodynamic evaluation in clinical practice.
- 1 April 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (2)
Open AccessRight Ventricular Mechanical Dyssynchrony Reflects Hemodynamic Load in Pre‐Capillary Pulmonary Hypertension
Right ventricular (RV) mechanical dyssynchrony represents a maladaptive response to increased afterload in pulmonary hypertension (PH). However, its hemodynamic and biochemical determinants remain unclear. This study aimed to identify the clinical, hemodynamic, and biochemical correlates of RV dyssynchrony in patients with pre‐capillary PH. Thirty patients with pre‐capillary PH (83% female; age 56 ± 19 years), all without intraventricular conduction delay (QRS < 120 ms), underwent right heart catheterization, cardiac magnetic resonance imaging, and two‐dimensional speckle‐tracking echocardiography. RV dyssynchrony was quantified using the coefficient of variation of time‐to‐peak systolic strain in four mid‐basal RV segments (RV‐CV4) adjusted for heart rate. Mean pulmonary artery pressure (mPAP), pulmonary vascular resistance (PVR), and RV‐CV4 averaged 34.1 ± 11.2 mmHg, 522.3 (interquartile range, 289.4–692.6) dyn·s·cm −5 , and 0.134 ± 0.083, respectively, in a cohort with predominantly mild‐to‐moderate RV systolic dysfunction. RV dyssynchrony correlated significantly with mPAP ( β = 0.509) PVR ( β = 0.507), and RV‐pulmonary artery coupling ( β = −0.406) (all p < 0.05). In multivariate analysis, mPAP remained the sole independent predictor of RV dyssynchrony ( β = 0.509, 95% CI 0.001–0.006, p = 0.004), accounting for 26% of its variance. Neither RV end‐diastolic volume nor RV ejection fraction were independently associated with dyssynchrony. RV mechanical dyssynchrony reflects hemodynamic afterload, particularly elevated mPAP, rather than structural remodeling. Notably, dyssynchrony was evident even in mild‐to‐moderate RV dysfunction, indicating an early manifestation of pressure‐induced impairment. RV‐CV4 may serve as a noninvasive marker of pulmonary vascular load and highlight the importance of afterload reduction in optimizing RV mechanical coordination. Accordingly, RV dyssynchrony assessment may provide a practical echocardiographic surrogate for invasive hemodynamic evaluation in clinical practice.
- Open Access
- 1 April 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 28 (4) , 807-818
Baseline characteristics of patients with transthyretin amyloid cardiomyopathy in the CARDIO-TTRansform trial of eplontersen
Aims: Eplontersen is an antisense oligonucleotide that suppresses hepatic production of circulating transthyretin (TTR) by targeting TTR mRNA. We present baseline data from an ongoing trial, CARDIO-TTRansform, evaluating eplontersen in patients with TTR amyloid cardiomyopathy (ATTR-CM) and compare findings across previous ATTR-CM trials. Methods and results: We evaluated 1432 patients enrolled in CARDIO-TTRansform from March 2020 to July 2023 who received ≥1 dose of study intervention (eplontersen or placebo) and had ≥1 post-baseline measurement. Mean (standard deviation) age was 76.4 (7.1) years; 9.4% were female; 88.8% were White. A total of 211 (14.7%) patients had hereditary/variant ATTR-CM (ATTRv-CM); Val122Ile (p.Val142Ile) was the most common genotype (n = 130). Patients spanned New York Heart Association functional classes I (n = 192), II (n = 997), and III (n = 243); 62.6% were National Amyloidosis Centre disease stage 1. Median (interquartile range) N-terminal pro-B-type natriuretic peptide was 2025 (1296–3465) pg/ml; n = 51 measured >8500 pg/ml. Median (interquartile range) high-sensitivity troponin T was 50 (35–69) pg/ml and mean left ventricular ejection fraction was 55.7% (9.7%). At baseline, 57.2% were on TTR stabilizer; 18.4% were on sodium-glucose co-transporter-2 inhibitors. Conclusion: The baseline characteristics of CARDIO-TTRansform were consistent with previous ATTR-CM trials; however, CARDIO-TTRansform evaluated patients with a wide range of disease severity and receiving the contemporary standard of care for ATTR-CM. Overall, blinded baseline data suggest that CARDIO-TTRansform provides a unique opportunity to determine the clinical benefits of eplontersen in a contemporary setting and in clinically relevant subgroups of patients with ATTR-CM. Trial registration number: NCT04136171
- 1 April 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 28 (4) , 807-818
Open AccessBaseline characteristics of patients with transthyretin amyloid cardiomyopathy in the CARDIO-TTRansform trial of eplontersen
Aims: Eplontersen is an antisense oligonucleotide that suppresses hepatic production of circulating transthyretin (TTR) by targeting TTR mRNA. We present baseline data from an ongoing trial, CARDIO-TTRansform, evaluating eplontersen in patients with TTR amyloid cardiomyopathy (ATTR-CM) and compare findings across previous ATTR-CM trials. Methods and results: We evaluated 1432 patients enrolled in CARDIO-TTRansform from March 2020 to July 2023 who received ≥1 dose of study intervention (eplontersen or placebo) and had ≥1 post-baseline measurement. Mean (standard deviation) age was 76.4 (7.1) years; 9.4% were female; 88.8% were White. A total of 211 (14.7%) patients had hereditary/variant ATTR-CM (ATTRv-CM); Val122Ile (p.Val142Ile) was the most common genotype (n = 130). Patients spanned New York Heart Association functional classes I (n = 192), II (n = 997), and III (n = 243); 62.6% were National Amyloidosis Centre disease stage 1. Median (interquartile range) N-terminal pro-B-type natriuretic peptide was 2025 (1296–3465) pg/ml; n = 51 measured >8500 pg/ml. Median (interquartile range) high-sensitivity troponin T was 50 (35–69) pg/ml and mean left ventricular ejection fraction was 55.7% (9.7%). At baseline, 57.2% were on TTR stabilizer; 18.4% were on sodium-glucose co-transporter-2 inhibitors. Conclusion: The baseline characteristics of CARDIO-TTRansform were consistent with previous ATTR-CM trials; however, CARDIO-TTRansform evaluated patients with a wide range of disease severity and receiving the contemporary standard of care for ATTR-CM. Overall, blinded baseline data suggest that CARDIO-TTRansform provides a unique opportunity to determine the clinical benefits of eplontersen in a contemporary setting and in clinically relevant subgroups of patients with ATTR-CM. Trial registration number: NCT04136171